A multicenter, open comparative study of parenteral cefotaxime and ceftriaxone in the treatment of nosocomial lower respiratory tract infections.

Abstract

A multicenter Canadian study enrolled 74 persons to compare low-dose cefotaxime at 1 g every 8 hr to ceftriaxone 1 g every 12 hr in patients with nosocomial pneumonia. Of 57 evaluable patients (30 cefotaxime and 27 ceftriaxone) in this preliminary report, 93% responded to therapy in both groups. Ceftriaxone patients tended to have more side effects (14.2%). This study is continuing to accrue patients to achieve 100 evaluable patients. Interim data, however, support the continued use of low-dose cefotaxime as an appropriate alternative for clinically effective and cost-effective management of nosocomially acquired pneumonia.

• Authors: G E Garber, P Auger, R M Chan, J M Conly, S D Shafran, M Gerson
• Journal: Diagnostic microbiology and infectious disease (Diagn Microbiol Infect Dis) Vol. 15 Issue 1 Pg. 85-8 (Jan 1992) ISSN: 0732-8893 [Print] United States
• PMID: 1730189 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Ceftriaxone
• Cefotaxime

Topics

• Adult
• Aged
• Aged, 80 and over
• Cefotaxime (administration & dosage, therapeutic use)
• Ceftriaxone (administration & dosage, therapeutic use)
• Cross Infection (drug therapy)
• Female
• Humans
• Injections, Intravenous
• Male
• Middle Aged
• Pneumonia (drug therapy)